Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET

Rhea-AI Summary

Brooklyn ImmunoTherapeutics (NYSE American: BTX) announced a conference call scheduled for May 25, 2021, at 4:30 p.m. ET. Participants must pre-register to receive the dial-in information. The call will address the company's exploration of cytokine and gene editing therapies for cancer and blood disorders. The lead program, IRX-2, is undergoing a Phase 2A trial, showing promising survival benefits for head and neck cancer patients. The company aims to advance treatments through newly acquired gene editing licenses.

Positive

• IRX-2 Phase 2A trial demonstrated overall survival benefits in head and neck cancer.
• Acquisition of licenses from Factor Bioscience and Novellus Therapeutics expands therapeutic opportunities.

Negative

• None.

Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn" or the “Company”), a biopharmaceutical company currently focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders and monogenic diseases, today announced that management will host a conference call on Tuesday, May 25, 2021 at 4:30 p.m. Eastern Time (ET).

Participants are asked to pre-register for the call through the following link: http://www.directeventreg.com/registration/event/6819283. Please note that registered participants will receive their dial in number upon registration and will dial directly into the call.

The conference call will also be available through a live webcast found here.

The Company invites participants to pre-submit questions to investors@brooklyntx.com until 5:00 p.m. Eastern Time (ET) on May 20, 2021 (live questions will not be accepted during the call). Please use the subject line, “BTX Call Questions” for this correspondence. The Company will do its best to address all pre-submitted questions at the conclusion of prepared remarks.

About Brooklyn ImmunoTherapeutics

Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also expoloring opportunities to advance oncology, blood disorders, and monogenic disease therapies using leading edge gene editing/cell therapy technology through the newly acquired license from Factor Bioscience Limited and Novellus Therapeutics Limited.

Brooklyn’s most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.

For more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210518005370/en/

FAQ

What is Brooklyn ImmunoTherapeutics focusing on?

Brooklyn ImmunoTherapeutics focuses on cytokine and gene editing therapies for cancer, blood disorders, and monogenic diseases.

When is the Brooklyn ImmunoTherapeutics conference call?

The conference call is scheduled for May 25, 2021, at 4:30 p.m. Eastern Time.

What therapy is Brooklyn ImmunoTherapeutics studying in clinical trials?

The company is studying IRX-2 in a Phase 2A clinical trial for head and neck cancer.

How can I submit questions for the Brooklyn ImmunoTherapeutics call?

Questions can be pre-submitted via email to investors@brooklyntx.com until May 20, 2021, at 5:00 p.m. ET.